The process starts with the collection of plasma samples of the disease under study and appropriate control samples followed by the removal of the most abundant plasma proteins to produce a natural complex antigen mix. Hybridoma antibody libraries are then generated and clones that differentially detect epitopes between plasma samples from patients and controls detected in a competition ELISA screening assay . Following further qualification, the selected clones are assembled into epitope-specific libraries for the development of diagnostic assays and clinical testing.